Form 4 for BCAX Bicara Therapeutics Inc.
Accepted 2025-09-17 00:00:00 ET · period of report 2025-09-15 · accession 0001883986-25-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-09-17 | 2025-09-15 | BCAX | Meisner Lara | CLO | S - Sale+OE | $11.49 | -15.8K | 0 | -100% | -$181.9K |
| D | 2025-09-17 | 2025-09-15 | BCAX | Meisner Lara | CLO | M - OptEx | $5.45 | +15.8K | 15.8K | New | +$86.3K |
| DM | 2025-09-17 | 2025-09-15 | BCAX | Meisner Lara | CLO | M - OptEx | $0.00 | -15.8K | 87.7K | -15% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-15 | S | D | 15,829 | $11.49 | 0 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $11.34 to $11.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |
| 2 | Common | Common Stock | 2025-09-15 | M | A | 15,829 | $5.45 | 15,829 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2025-09-15 | M | D | 6,085 | $0.00 | 54,769 | D | $5.45 · — to 2033-12-14 | 6,085 Common Stock | (F3) The shares underlying this option vest in sixteen equal quarterly installments following December 14, 2023, subject to the Reporting Person's continued service on each such vesting date. |
| 4 | Derivative | Stock Option (Right to Buy) | 2025-09-15 | M | D | 9,744 | $0.00 | 87,699 | D | $5.45 · — to 2033-12-14 | 9,744 Common Stock | (F4) 25% of the shares underlying this option vested on November 27, 2024, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |